GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (FRA:PCJ) » Definitions » Inventories, Finished Goods

Abeona Therapeutics (FRA:PCJ) Inventories, Finished Goods : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 1980. Start your Free Trial

What is Abeona Therapeutics Inventories, Finished Goods?


Abeona Therapeutics Inventories, Finished Goods Historical Data

The historical data trend for Abeona Therapeutics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abeona Therapeutics Inventories, Finished Goods Chart

Abeona Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Abeona Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Abeona Therapeutics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


Abeona Therapeutics Business Description

Traded in Other Exchanges
Address
6555 Carnegie Avenue, 4th Floor, Cleveland, OH, USA, 44103
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.

Abeona Therapeutics Headlines

No Headlines